Combination of Heme Oxygenase-1 Inhibition and Sigma Receptor Modulation for Anticancer Activity

• Published in: Molecules (Basel, Switzerland) Switzerland), 2021-06, Vol.26 (13), p.3860
• Main Authors: Romeo, Giuseppe, Ciaffaglione, Valeria, Amata, Emanuele, Dichiara, Maria, Calabrese, Loredana, Vanella, Luca, Sorrenti, Valeria, Grosso, Salvo, D’Amico, Agata Grazia, D’Agata, Velia, Intagliata, Sebastiano, Salerno, Loredana
• Format: Article
• Language: English
• Subjects: anticancer activity; Antitumor activity; Binding sites; Brain cancer; Cancer; Cancer therapies; Cell growth; Cell proliferation; Communication; DU145; Enzymes; Glioblastoma; Heme; heme oxygenase; Heme oxygenase (decyclizing); HO-1 inhibitors; Hybrids; Invasiveness; Ligands; Metabolism; Narcotics; Oxygenase; Physiology; Prostate; Prostate cancer; Sigma receptors; σR ligands
• ISSN: 1420-3049; 1420-3049
• DOI: 10.3390/molecules26133860

Cancer is a multifactorial disease that may be tackled by targeting different signaling pathways. Heme oxygenase-1 (HO-1) and sigma receptors (σRs) are both overexpressed in different human cancers, including prostate and brain, contributing to the cancer spreading. In the present study, we investigated whether HO-1 inhibitors and σR ligands, as well a combination of the two, may influence DU145 human prostate and U87MG human glioblastoma cancer cells proliferation. In addition, we synthesized, characterized, and tested a small series of novel hybrid compounds (HO-1/σRs) 1–4 containing the chemical features needed for HO-1 inhibition and σR modulation. Herein, we report for the first time that targeting simultaneously HO-1 and σR proteins may be a good strategy to achieve increased antiproliferative activity against DU145 and U87MG cells, with respect to the mono administration of the parent compounds. The obtained outcomes provide an initial proof of concept useful to further optimize the structure of HO-1/σRs hybrids to develop novel potential anticancer agents.